SIGA Technologies Funding Round

10/28/2026

Debt

$15,000,000

Undisclosed

The contract will fund the procurement and supply of oral TPOXX® (tecovirimat), an antiviral medication used to treat smallpox, for the Canadian Department of National Defence through its Strategic Medical Countermeasures Program. The agreement will help maintain access to this approved medical countermeasure for the Canadian Armed Forces, strengthening military medical preparedness and Canada's ability to respond to a potential smallpox outbreak or other public health emergency. The contract provides for purchases of up to approximately $15 million by March 31, 2031, including approximately $9 million in firm commitments over the first three years and a further $6 million subject to the exercise of purchase options.

Private & Independent

Biopharmaceutical

31 East 62nd Street
New York, NY 10065
US

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox is particularly worrisome because it is highly infectious and deadly. We are developing best-in-class products to treat this infection in patients worldwide.?